SHERMAN JEFFREY W
SEC insider (Form 3/4/5 filer). CIK 0001230482. Director at Larimar Therapeutics, Inc. (LRMR) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on May 19, 2026. Located in BALA CYNWYD, PA.
Companies SHERMAN JEFFREY W has filed insider reports for
- Larimar Therapeutics, Inc. (LRMR): Director
- Xeris Biopharma Holdings, Inc. (XERS): Director
SHERMAN JEFFREY W
CIK: 0001230482
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- May 19, 2026LRMR
Larimar Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
55.2K shares- - Feb 27, 2026LRMR
Larimar Therapeutics, Inc.
PurchaseDirect5K shares at avg. $5.00$25K - Aug 28, 2025XERS
Xeris Biopharma Holdings, Inc.
ExerciseDirect47K shares at avg. $6.66$313K - Aug 28, 2025XERS
Xeris Biopharma Holdings, Inc.
SaleDirect42.2K shares at avg. $7.92$335K - Jun 4, 2025XERS
Xeris Biopharma Holdings, Inc.
AwardDirect50K shares- - May 13, 2025LRMR
Larimar Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
19K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 19, 2026 |  LRMR Larimar Therapeutics, Inc. | Award Stock Option (Right to Buy) | 55,150 | - | - | Direct |
| Feb 27, 2026 | LRMR Larimar Therapeutics, Inc. | Purchase | 5,000 | $5.00 | $25,000 | Direct |
| Aug 28, 2025 |  XERS Xeris Biopharma Holdings, Inc. | Exercise | 47,040 | $6.66 | $313,286 | Direct |
| Aug 28, 2025 | XERS Xeris Biopharma Holdings, Inc. | Sale | 42,232 | $7.92 | $334,515 | Direct |
| Jun 4, 2025 | XERS Xeris Biopharma Holdings, Inc. | Award | 50,000 | - | - | Direct |
| May 13, 2025 | LRMR Larimar Therapeutics, Inc. | Award Stock Option (Right to Buy) | 19,000 | - | - | Direct |
1-6 of 6 transactions